WO2011073419A1 - Nouveaux inhibiteurs stéroïdiens de pgp pour emploi dans l'inhibition de la résistance pléiotrope - Google Patents

Nouveaux inhibiteurs stéroïdiens de pgp pour emploi dans l'inhibition de la résistance pléiotrope Download PDF

Info

Publication number
WO2011073419A1
WO2011073419A1 PCT/EP2010/070141 EP2010070141W WO2011073419A1 WO 2011073419 A1 WO2011073419 A1 WO 2011073419A1 EP 2010070141 W EP2010070141 W EP 2010070141W WO 2011073419 A1 WO2011073419 A1 WO 2011073419A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl acetate
compound
othp
formula
mmol
Prior art date
Application number
PCT/EP2010/070141
Other languages
English (en)
Inventor
Catherine Grenot
Claude Cuilleron
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority to EP10788352A priority Critical patent/EP2512485A1/fr
Priority to JP2012543802A priority patent/JP2013514338A/ja
Priority to US13/516,860 priority patent/US20120309728A1/en
Publication of WO2011073419A1 publication Critical patent/WO2011073419A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Definitions

  • the present invention concerns new steroid inhibitors of Pgp for use for inhibiting multidrug resistance.
  • MDR phenotype multidrug resistance phenotype
  • agents already in use for other medical indications such as verapamil or cyclosporine
  • Comparisons of these compounds and of their reversal activities have revealed structural features increasing the inhibitory effects (J. Robert and C. Jarry, Multidrug resistance reversal agents, J Med Chem 46 (2003) 4805-4817).
  • significant improvements remain to be accomplished to decrease enough the side-effects to allow the development of efficient drugs.
  • the aim of the present invention is to provide new Pgp inhibitors having an intrinsic pharmacological activity with no toxic side effects.
  • the present invention relates to a compound of formula (I):
  • R 9 is a 5 to 7 membered heterocyclyl or (CH 2 ) p OAIk;
  • R 13 is CrC 6 alkyl, (CH 2 ) r OHet, (CH 2 ) r SAr or (CH 2 ) r SAIk,
  • R16 and Ri 7 are each independently selected from C C 6 alkyl
  • R 18 is H or C C 6 alkyl
  • R 6 when R 6 is other than H and R 7 is H, then at least one of R 3 , R' 3 , R 4 and/or R 5 is other than H, and when R 6 is COCH 3 and R 7 is OH, then at least one of R 3 , R' 3 , R 4 and/or R 5 is other than H.
  • Multidrug resistance is a major limit for chemotherapy treatments of cancers.
  • the predominant MDR mechanism is a reduced cytotoxic drug accumulation consecutive to the active efflux of drugs by energy-dependent transporters belonging to the ATP-binding cassette (ABC) family.
  • the major contribution comes from P-glycoprotein (Pgp or ABCB1 ) encoded by MDR1 gene, which exports xenobiotics out of cells, as well as a wide variety of cytotoxic drugs (E. Teodori et al., Current Drug Targets 7 (2006) 896-909) and is often found overexpressed in resistant tumors.
  • Two other proteins, MRP1 (Multidrug Resistance Protein 1 , ABCC1 ) and BCRP (Breast Cancer Resistance Protein, ABCG1 ) may also often contribute, although to a lower extent, to the drug efflux.
  • Pgp is a glycoprotein of 1280 amino acids organized in two domains of 610 amino acids joined by a linker region of 60 residues. Each domain contains six transmembrane segments, separated by hydrophilic loops and a cytoplasmic hydrophilic nucleotide-binding domain (NBD) containing the well-conserved Walker A and B sequence motifs characterizing ATP binding sites (M.M. Gottesman et al., Nat Rev Cancer 21 (2002) 48-58). Photoaffinity labeling and mutagenesis experiments have suggested that the drug binding domain is located within the transmembrane domains in both halves of the protein (E.P.
  • alkyl (or Alk) means a saturated or unsaturated aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain.
  • Branched means that one or lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain.
  • Lower alkyl » means 1 to 4 carbon atoms in the chain which may be straight or branched.
  • alkoxy refers to an -O-alkyl radical.
  • halo refers to the atoms of the group 17 of the periodic table (halogens) and includes in particular fluorine, chlorine, bromine, and iodine atom.
  • aryl refers to an aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring system, wherein any ring atom capable of substitution may be substituted by a substituent.
  • aryl moieties include, but are not limited to, phenyl, naphthyl, and anthracenyl.
  • aryl also includes “heteroaryl” which refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 1 1 -14 membered tricyclic ring system having 1 -3 heteroatoms if monocyclic, 1 -6 heteroatoms if bicyclic, or 1 -9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e. g. , carbon atoms and 1 -3, 1 -6, or 1 -9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein any ring atom capable of substitution may be substituted by a substituent.
  • heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 1 1 -14 membered tricyclic ring system having 1 -3 heteroatoms if monocyclic, 1 -6 heteroatoms if bicyclic, or 1 -9 heteroatoms if tricyclic, said hetero
  • heterocyclyl refers to a nonaromatic 5-7 membered monocyclic, ring system having 1 -3 heteroatoms, said heteroatoms being selected from O, N, or S (e. g. , carbon atoms and 1 -3 heteroatoms of N, O, or S), wherein any ring atom capable of substitution may be substituted by a substituent.
  • substituted refers to a group "substituted” on an alkyl, heterocyclyl or aryl group at any atom of that group. Suitable substituents include, without limitation, alkyl, alkenyl, alkynyl, alkoxy, halo, hydroxy, cyano, nitro, amino, S0 3 H, sulfate, phosphate, perfluoroalkyl, perfluoroalkoxy, methylenedioxy, ethylenedioxy, carboxyl, oxo, thioxo, imino (alkyl, aryl, aralkyl), S(0) n alkyl (where n is 0-2), S(0) n aryl (where n is 0-2), S(0) n heteroaryl (where n is 0-2), S(0) n heterocyclyl (where n is 0- 2), amine (mono-, di-, alkyl, cycloalkyl, a
  • acyl refers to an alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, or heteroarylcarbonyl substituent, any of which may be further substituted by substituents.
  • oxo refers to an oxygen atom, which forms a carbonyl when attached to carbon, an N-oxide when attached to nitrogen, and a sulfoxide or sulfone when attached to sulfur.
  • alkenyl as employed herein includes partially unsaturated, nonaromatic, hydrocarbon groups having 2 to 12 carbons, preferably 2 to 6 carbons.
  • the compounds herein described may have asymmetric centers.
  • Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well-known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a compound are intended, unless the stereochemistry or the isomeric form is specifically indicated.
  • “Pharmaceutically acceptable” means it is, within the scope of sound medical judgment, suitable for use in contact with the cells of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salt refers to salts which retain the biological effectiveness and properties of the compounds of the invention and which are not biologically or otherwise undesirable.
  • the compounds of the invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids, while pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases.
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • compositions both for veterinary and for human use, useful according to the present invention comprise at least one compound having formula (I) as above defined, together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients.
  • active ingredients necessary in combination therapy may be combined in a single pharmaceutical composition for simultaneous administration.
  • compositions, carriers, diluents and reagents are used interchangeably and represent that the materials are capable of administration to or upon a mammal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
  • compositions that contains active ingredients dissolved or dispersed therein are well understood in the art and need not be limited based on formulation.
  • compositions are prepared as injectables either as liquid solutions or suspensions; however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared.
  • the preparation can also be emulsified.
  • the pharmaceutical compositions may be formulated in solid dosage form, for example capsules, tablets, pills, powders, dragees or granules.
  • excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used for preparing tablets.
  • lactose and high molecular weight polyethylene glycols When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension.
  • Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.
  • Total daily dose of the compounds of the invention administered to a subject in single or divided doses may be in amounts, for example, of from about 0.001 to about 100 mg/kg body weight daily and preferably 0.01 to 10 mg/kg/day. Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the body weight, general health, sex, diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.
  • the compounds of formula (I) above are used for reversing or inhibiting multidrug resistance in cancer, or in bacterial, fungal or parasitic infections.
  • the present invention relates to the compound of formula (I) as defined above for its use for reversing or inhibiting multidrug resistance in cancer.
  • said compounds of formula (I) are administered together with an antitumoral medicine.
  • (A) is (lb) as defined above.
  • At least one of R 3 , R' 3 , R 4 and/or R 5 is other than H.
  • R 5 is H or OR 9 , more preferably H or 2-oxytetrahydropyranyl.
  • R 8 is preferably a 5 to 7 membered cycloalkyl group in which one or more ring carbon atoms are replaced by at least one hetero atom -0-. More preferably, R 8 is a 2-tetrahydropyranyl.
  • the present invention also relates to a compound of formula (II):
  • R 3 , R' 3 , R 4 , R 5 , R 6 and R 7 are as defined above in formula (I), for its use for reversing or inhibiting multidrug resistance.
  • R 3 , R 6 and R 7 are as defined above in formula (II).
  • R 3 is H.
  • R 3 is other than H.
  • R 3 is OH or OR 8 , R 8 being as defined above and being preferably a heterocyclyl (such as tetrahydropyranyl).
  • R 6 and R 7 are each independently selected from H, CORi3, and OR , R13 being preferably alkyl and R being preferably a heterocycle.
  • the present invention also relates to a compound having the following formula
  • At least one of R 3 , R' 3 , R 4 and/or R 5 is other than H.
  • the present invention also relates to a compound of formula
  • At least one of R 3 , R' 3 , R 4 and/or R 5 is other than H.
  • R 3 is -OCOPh, 2-oxytetrahydropyranyl or OR 8 , R 8 being preferably a heterocyclic group.
  • the dot in the formula (III) indicates the position of H (R 2 of formula (I)).
  • the compounds of formula (III) are 5 ⁇ - ⁇ derivatives.
  • the present invention also relates to a compound of formula (III-1 ):
  • R 3 and R 4 are other than H.
  • R 3 is selected from OR 8 (Rs being preferably a heterocyclyl group), OCOAr and H.
  • R 6 is COR 13 .
  • R 8 being preferably a heterocyclyl group
  • OCOAr preferably a heterocyclyl group
  • R 3 , R 8 and Ri 3 being as defined above in formula (I), and R 3 being preferably selected from 0R 8 (R 8 being preferably a heterocyclyl group), OCOAr and H.
  • At least one of R 3 and R 4 is other than H.
  • the compounds of formula (IV) are 5oc-H derivatives.
  • R 3 is OCOAr.
  • R 6 is CORi 3 .
  • R 4 is H.
  • R 3 , R 4 , and R 5 being as defined above in formula (I).
  • At least one of R 3 , R 4 and/or R 5 is other than H.
  • R 3 and R 4 are selected from OR 8 and OCOAr, R 8 being preferably a heterocycle (such as 2-tetrahydropyranyl).
  • R 4 is H, and R 3 and R 4 are selected from OR 8 and OCOAr, R 8 being preferably a heterocycle.
  • the present invention also relates to a compound of formula (VI):
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) as defined above, in admixture with one or more pharmaceutically acceptable excipients,
  • the compounds 103(R+S) CAS[492453-63-1 ] and 9 (R+S) CAS[29371 -92-4] as mentioned above are in the form of racemic mixtures.
  • the present invention also relates to a pharmaceutical composition comprising a compound of formula (VIII
  • R 3 , R' 3 , R 4 and/or R 5 is other than H.
  • the present invention also relates to a pharmaceutical composition comprising a compound of formula (II) as defined above, in admixture with one or more pharmaceutically acceptable excipients, with the exclusion of the compounds 103(R+S) CAS[492453-63-1 ] and 9 (R+S) CAS[29371 -92-4] as mentioned above.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) as defined above wherein R 3 is other than H, in admixture with one or more pharmaceutically acceptable excipients.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula
  • R 3 , R' 3 , R 4 , R 5 , R 6 and R 7 are as defined above in formula (I), in admixture with one or more pharmaceutically acceptable excipients.
  • the hydrogen atom in position 5 is either in a- or ⁇ -position.
  • At least one of R 3 , R' 3 , R 4 and/or R 5 is other than H.
  • the present invention also relates to compounds having formula (11-1 ):
  • the present invention also relates to compounds having formula (III) as defined above,
  • the present invention also relates to compounds having formula (IV-1 ), (V-1 ) or (VI) as defined above.
  • the present invention also relates to compounds having formula (V) or (V-2) as defined above, with the exclusion of
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising one of said preferred compounds, in association with at least one pharmaceutically acceptable excipient, as well as said compounds for their use for reversing or inhibiting multidrug resistance.
  • Figures 1 and 2 represent the effects of treatment with different cytotoxics with a concentration varying from 0.001 ⁇ to 100 ⁇ for 24 h on survival of H295R and R7 cells, evaluated by [ 3 H]thymidine incorporation. They represent the ratio of [ 3 H]thymidine incorporation (in %) in surviving cells (1 : K562/R7 and 2: H295R cells) as a function of the concentration in ⁇ of several cytotoxic drugs.
  • the curve with black circles relates to doxorubicin; the curve with white circles relates to vinorelbine; the curve with black triangles relates to taxol; the curve with white triangles relates to vinblastine; the curve with the black squares relates to mitoxantrone and the curve with white squares relates to colchicine.
  • Figures 3 and 4 represent the effects of compounds of the invention (steroid modulators) on chemosensitization of resistant R7 cells to doxorubicin (DOXO), evaluated by [ 3 H]thymidine incorporation.
  • Resistant R7 cells were incubated for 24 hours with increasing concentrations of doxorubicinin the absence (o) or in the presence of said steroid modulators.
  • the sensitive K562 cells were incubated with the same concentrations of doxorubicin ( ⁇ ).
  • the curve with the black triangles ( T) relates to progesterone at 3 ⁇ ;
  • the curve with white lozenges (0) relates to compound (30) at 0.4 ⁇ ;
  • the curve with black squares ( ⁇ ) relates to compound (33) at 0.4 ⁇ ;
  • the curve with white squares ( ⁇ ) relates to compound (41 ) at 0.5 ⁇ ;
  • the curve with black lozenges ( ⁇ ) relates to compound (51 ) at 0.5 ⁇ ;
  • the curve with black triangles ( A) relates to cyclosporine A at 0.4 ⁇ .
  • Figure 5 represents the competitive binding assay of compounds of the invention to progesterone receptor.
  • the ratio B/B° is represented as a function of the concentration of the tested compounds (in ⁇ ).
  • the curve with black lozenges ( ⁇ ) relates to ORG2054; the curve with black squares ( ⁇ ) relates to compound (30); the curve with black circles ( ⁇ ) relates to compound (33); the curve with black stars (*) relates to compound (41 ); the curve with black triangles ( A) relates to compound (53) and the curve with white triangles ( ⁇ ) relates to compounds (59)+(62).
  • Figure 6 represents the activation of hPXR receptor by compounds of the invention using SR6 (synthetic cholesterol-lowering drug) as a positive control (curve with squares) ⁇ ).
  • the tested compounds are: 10 (4), 1 1 ( ⁇ ), 30 (+), 33 ( ⁇ ), 40 (-), 41 ( ⁇ ), 51 (x), 52 (T), 53 ( ⁇ ), 59+62 (A).
  • the luciferase activity (RLU) is represented as a function of the concentration of the compounds in M.
  • Figures 7 and 8 represent the tumour volume of mice treated with vehicle ( ⁇ ), doxorubicin (o), compound (33) alone (T ), and compound (33) with doxorubicin ( ⁇ ).
  • the tumor volume is indicated as a function of days.
  • Figure 7 concerns mice xenografted with H295R cells and
  • Figure 8 concerns mice xenografted with R7 cells (the arrow indicates the beginning of treatment of mice).
  • the com ound (3) is prepared according to the following reaction scheme:
  • the product was purified by preparative TLC on fluorescent silica gel in similar conditions to give the pure 7beta-ol isomer 1 (55 mg) as the more retained product and the 7alpha-ol isomer (19 mg).
  • the 7beta-hydroxy derivative 2 (6 mg, 0.018 mmol, 1 .0 Eq.) was stirred for 1 h at room temperature in an extemporaneously prepared solution containing anhydrous THF (0.42 ml_), freshly distilled dihydropyrane (0.08 ml_) and p- toluenesulfonic acid (0.4 mg). The reaction was stopped by addition of an excess of a saturated NaHC0 3 solution.
  • Example 2 Preparation of 11 -mono-substituted (5beta-H)pregnane-3,20- dione derivatives (6) and (7)
  • reaction mixture was filtered on a pad of TMCelite and evaporated under reduced pressure.
  • the residual pyridine was eliminated by azeotropic distillation in the presence of n-heptane.
  • the 1 l alpha-hydroxy derivative 4 (100 mg, 0.301 mmol, 1 .0 Eq.) was stirred for 1 h at rt° in an extemporaneously prepared solution containing anhydrous THF (2.50 ml_), freshly distilled dihydropyrane (0.50 ml_) and p-toluenesulfonic acid (2.5 mg). The reaction was stopped by addition of an excess of a saturated NaHC0 3 .
  • This example relates to the preparation of 17alpha-0-[2'(S)]Tetrahydro- pyranyloxypregn-4-ene-3,20-dione 10 and 17alpha-0-[2'(R)]Tetrahydropyranyl- oxypregn-4-ene-3,20-dione 1 1 havin the following formula:
  • 17alpha-Hydroxypregn-4-ene-3,20-dione (“17alpha-hydroxyprogesterone”) (50 mg, 0.151 mmol, 1 .0 Eq.) was stirred for 2 days at rt° in an extemporaneously prepared solution containing anhydrous THF (1 .25 mL), freshly distilled dihydropyrane (0.25 mL) and p-toluenesulfonic acid (1 .25 mg). Then the same amount of these reagents was further added and stirring was maintained for 5 days until most of the starting product was transformed. The reaction was stopped by addition of an excess of a saturated NaHC0 3 solution.
  • This example relates to the preparation of 3p,7oc-dibenzoyloxy(5alpha)- pregnan-20-one (18), according to the following reactions scheme:
  • pregnenolone 3beta-Hydroxypregn-5-en-20-one (pregnenolone) (10.0 g, 31 .598 mmol, 1 .0 Eq.) (Sigma) was stirred for 4 h at rt° with benzoyl chloride (10 mL, 86.149 mmol, 2.73 Eq.) dissolved in pyridine (200 mL). The reaction mixture was cooled at 4 ⁇ ⁇ and stirred for 30 min after addition of 150 mL of ethyl acetate and 150 mL of a saturated aqueous solution of NaHC0 3 .
  • the dry pregn-5-ene derivative 13 (5.0 g, 10.761 mmol, 1 .0 Eq.) was added to a vigorously stirred solution of anhydrous Cr0 3 -(pyridine) 2 complex (69.4 g, 269.025 mmol, 25 Eq.) (Mappus E. & Cuilleron C. Y., J. Chem. Res. 1979 [S] , 42-3; [M],501- 35) extemporaneously prepared at 4°C by addition of anhydrous pyridine and dry Cr0 3 in 760 ml_ of anhydrous dichloromethane. Stirring was maintained for 15 min at 4°C, then for 5 h at rt°.
  • reaction mixture was filtered on a column of Florisil ® and evaporated under reduced pressure.
  • the residual pyridine was eliminated by azeotropic distillation in the presence of n-heptane.
  • the column was washed with dichloromethane until no more product could be recovered after evaporation.
  • the crude extract (4.5 g) was analyzed by TLC on fluorescent silica gel (petroleum ether/ethyl acetate 3:1 ).
  • the 5-en-7-one derivative 14 (500 mg, 1 .045 mmol, 1 .0 Eq.) dissolved in a dioxane-95% ethanol 1 :1 v/v mixture containing 0.8% pyridine (42 mL) was introduced in a glass hydrogenation apparatus and magnetically stirred under hydrogen at atmospheric pressure, for 24 h at 30 'C, in the presence of 10% Pd-C catalyst (350 mg).
  • reaction mixture was filtered on a pad of TMCelite and evaporated under reduced pressure.
  • the 7alpha-hydroxy derivative 17 (50 mg, 0.1 14 mmol, 1 .0 Eq.) was stirred for 48 h at rt° with benzoyl chloride (0 037 ml, 2.8 Eq.) dissolved in pyridine (0.72 mL). The reaction mixture was cooled at 4°C, stirred for 30 min after addition of 0.8 mL of ethyl acetate and 0.8 mL of a saturated aqueous solution of NaHC0 3 .
  • the compound (30) is prepared according to the following reaction scheme:
  • H alpha- hydroxyprogesterone 1 1 alpha-hydroxypregn-4-ene-3,20-dione (Sigma) (10 g, 30.261 mmol, 1 .0 Eq.) in toluene (450 mL) containing ethyleneglycol (140 mL) and p-toluenesulfonic acid (0.6 g) was stirred for 5 h under reflux, using a Dean-Stark water trap. The reaction mixture was cooled at
  • reaction mixture was extracted by pouring it in 800 mL of water.
  • the solid precipitate of steroid derivative was collected by filtration and washed with water.
  • the solid residue was extracted with ethyl acetate.
  • the organic layer was washed with water, filtered on a phase-separating paper (Whatman), evaporated to dryness under reduced pressure and dried by azeotropic distillation with toluene under reduced pressure.
  • the dry pregn-5-ene derivative 22 (3.50 g, 6.569 mmol, 1 .0 Eq.) was stirred for 15 min at 4 ⁇ C, then 5 h at rt° in a solution of anhydrous Cr0 3 -(pyridine) 2 complex (42.368 g, 164.217 mmol, 25 Eq.), extemporaneously prepared at 4°C by addition of anhydrous pyridine and dry Cr0 3 in 400 mL of anhydrous dichloromethane.
  • the crude product was purified by flash-chromatography on silica gel (230- 400 mesh) using petroleum ether/ethyl acetate 3:1 as eluent to give the 5-en-7-one 23 (1 .02 g).
  • the pregn-5-en-7-one 23 (1 .576 g, 2.882 mmol, 1 .0 Eq.) dissolved in a dioxane-95% ethanol 1 :1 v/v mixture containing 0.8% pyridine (124 mL) was introduced in a glass hydrogenation apparatus and magnetically stirred under hydrogen at atmospheric pressure, for 24 h at 30 ⁇ , in the presence of 10% Pd-C catalyst (1 .1 1 g ).
  • reaction mixture was filtered on a pad of TMCelite and evaporated under reduced pressure.
  • the residual pyridine was eliminated by azeotropic distillation in the presence of n-heptane.
  • reaction mixture was stirred for 30 min with 6.67 mL of a 7 N aqueous solution of NaOH and 6.67 mL of 30% H 2 0 2 , evaporated under reduced pressure. After conventional extraction (ethyl acetate) the dry product (999 mg) was analyzed by TLC on fluorescent silica gel (petroleum ether/ethyl acetate 2:1 , 3:1 and 1 :1 ) which showed two spots corresponding to 7alpha- and 7beta-hydroxy isomers.
  • the crude residue was purified by flash-chromatography on silica gel (230-400 mesh) using petroleum ether/ethyl acetate 3:1 as eluent to give a pure sample of 7alpha-ol 25 (419 mg), the less retained isomer, and a sample of 7beta-ol byproduct 34 (vide infra) (452 mg) still containing a minor amount of the 7alpha-ol.
  • the (5beta)pregnan-7-one derivative 24 (3.64 g, 6.632 mmol, 1 .0 Eq.) dissolved in a mixture of THF (15 mL) and methanol (75 mL) was magnetically stirred under nitrogen for 48 h at rt° in the presence of NaBH 4 (300 mg, 7.93 mmol, 1 .2 Eq.). The reaction was cooled at 4°C and the excess of NaBH 4 was neutralized by addition of a mixture of acetone (10 mL), acetic acid (0.5 mL) and water (10 mL) at 4°C.
  • the 1 1 alpha-ie -butyldimethylsilyl derivative 26 (C654.95; 1 .50 g, 2. 290 mmol, 1 .0 Eq.) dissolved in THF (17 mL) was stirred for 12 h at 4 ⁇ C after addition of a commercial 1 M solution of tetra-butylammonium fluoride (14 mL, 14 mmol, 3.60 g, 6.02 Eq.) in THF.
  • the crude product was purified by flash-chromatography on silica gel (230- 400 mesh) using petroleum ether/ethyl acetate 2:1 as eluent to give a pure sample of 1 1 alpha-ol 27 (0.93 g).
  • the combined less-pure fractions were purified by preparative TLC on fluorescent silica gel (petroleum ether/ethyl acetate 1 :1 ) to give additional amounts of pure 1 1 alpha-ol.
  • Example 6.2 Preparation of 7oc-Benzoyloxy-1 1 a-0-[2'(S)]tetrahydropyranyloxy (5 )pregnane-3,20-dione (32) and 7oc-Benzoyloxy-1 1 oc-0-[2'(R)]tetrahydropyranyl- oxy(5 )pregnane-3,20-dione (33)
  • 7alpha-Benzoyloxy-1 1 alpha-hydroxy(5beta)pregnan-3,20-dione 28 (807 mg, 1 .783 mmol, 1 .0 Eq.) was stirred for 3 h at rt° in an extemporaneously prepared solution containing anhydrous THF (20 ml_), freshly distilled dihydropyrane (4 ml_) and p-toluenesulfonic acid (20 mg). The reaction was quenched with a cold saturated NaHC0 3 solution.
  • the two R/S isomers were separated by flash-chromatography on silica gel (230-400 mesh) using petroleum ether/ethyl acetate 2:1 as eluent. Three fractions were obtained corresponding respectively to the pure less retained isomer 32 (416 mg), the mixture of R/S isomers (340 mg) and the pure more retained isomer 33 (136 mg).
  • the mixture of two R/S isomers of the intermediate fraction could be further separated by preparative TLC (dichloromethane/ethyl acetate 2:1 , x 2 developments) yielding an additional pure sample of the less retained isomer.
  • Example 6.3 Preparation of 7 -benzoyloxy-1 1 oc-0-[2'(S)]tetrahydropyranyloxy (5 )pregnane-3,20-dione (39) and 7 -benzoyloxy-1 1 oc-0-[2'(R)]tetrahydropyranyloxy (5 )pregnane-3,20-dione (40)
  • This 7beta-ol compound was obtained as a by-product in the preparation of the 3,20-bisethylenedioxy-1 1 alpha-(te/?-butyl-dimethyl-silanyloxy)(5beta)pregnan- 7alpha-ol isomer 25 (vide supra).
  • a chromatographic fraction still containing a minor amount of alpha-isomer (Method A) was employed without further purification in the following next step.
  • the 7beta-hydroxy derivative 34 (400 mg, 0.726 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with benzoyl chloride (0.5 mL, 4.307 mmol, 5.93 Eq.) dissolved in pyridine (8 mL). The reaction mixture was cooled at 4 ⁇ C and stirred for 30 min after addition of 30 mL of ethyl acetate and 30 mL of a saturated aqueous solution of NaHC0 3 .
  • the 7beta-benzoate derivative 35 (250 mg, 0.382 mmol, 1 .0 Eq.) dissolved in THF (2.8 mL) was stirred for 72 h at 4 ⁇ C after addition of a commercial 1 M solution of tetra-butylammonium fluoride (1 .147 mL, 3.01 Eq.) in THF. A same amount of reagent was further added and stirring was prolonged for 24 h at rt°.
  • the 1 1 alpha-hydroxy derivative 37 (90 mg, 0.199 mmol, 1 .0 Eq.) was stirred for 12 h at rt° in an extemporaneously prepared solution containing anhydrous THF (2.25 ml_), freshly distilled dihydropyrane (0.45 ml_) and p-toluenesulfonic acid (2.25 mg). The reaction was stopped by addition of an excess of a saturated NaHC0 3 solution.
  • the 1 l alpha-hydroxy derivative 37 (45 mg, 0.099 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with benzoyl chloride (0.068 mL, 0.586 mmol, 5.89 Eq.) dissolved in pyridine (1 .1 mL).
  • the reaction mixture was cooled in an ice-bath at 4°C and stirred for 30 min after addition of 4 mL of ethyl acetate and 4 mL of a saturated aqueous solution of NaHC0 3 .
  • the 1 1 alpha-hydroxy derivative 42 (15 g, 40.052 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with an excess of acetic anhydride (60 mL) dissolved in pyridine (300 mL).
  • the crude product was purified by flash-chromatography on silica gel (230- 400 mesh) using dichloromethane/ethyl acetate 1 :1 as eluent to give the pure 1 1 - acetate 43.
  • the aqueous layer was separated and extracted several times with dichloromethane.
  • the combined organic layers were washed with water, filtered on a phase-separating paper (Whatman) and evaporated to dryness under reduced pressure.
  • the crude extract was analyzed by TLC on fluorescent silica gel (petroleum ether/ethyl acetate 1 :3 Rf 0.31 ).
  • reaction mixture was filtered on a pad of TMCelite and evaporated under reduced pressure.
  • the residual pyridine was eliminated by azeotropic distillation in the presence of n-heptane.
  • the dry product (357 mg) was analyzed by TLC on fluorescent silica gel (petroleum ether/ethyl acetate 1 :1 ) to give a major non-UV-absorbing spot.
  • This 4,5- dihydrogenated product 46 was employed without further purification in the following next step.
  • the 1 1 oc-acetoxy derivative 46 (356 mg, 0.912 mmol, 1 .0 Eq.) was stirred in a solution of K 2 C0 3 (400 mg) in a mixture of methanol (35 mL) and water (5 mL) for 48 h at 50 'C under nitrogen atmosphere.
  • the 1 1 a,17a-diol 47 (100 mg, 0.287 mmol, 1 .0 Eq.) was stirred for 4 h at rt° in an extemporaneously prepared solution containing anhydrous THF (0.833 mL), freshly distilled dihydropyrane (0.166 mL) and p-toluenesulfonic acid (1 mg). The reaction was stopped by addition of an excess of a saturated NaHC0 3 solution.
  • Example 8 Preparation of 7,12-disubstituted (5 -H)cholane derivatives (57), (59), (60), (63), (64), (71 ), (73) and (74)
  • Methyl 3alpha,7alpha, 12alpha-trihydroxycholanate 55 200 mg, 0.473 mmol, 1 .0 Eq.
  • dissolved in toluene 40 mL was magnetically stirred for 1 2 h under reflux in a Dean-Stark water trap in the presence of 2.0 g of Ag 2 C0 3 /Celite reagent (cf Fieser L., Reagents for Organic Synthesis, Vol 2, p. 363; Fetizon M., Balogh V., Golfier M., J. Org. Chem. (1971), 36, 1339-41).
  • reaction mixture was filtered on a column of Celite which was washed with an excess of toluene.
  • the combined filtrates were evaporated under reduced pressure.
  • the white extract was analyzed by TLC on fluorescent silica gel (chloroform/ethyl acetate 1 :3), showing a major spot above the starting product.
  • This mono-3-oxo product 56 was employed without further purification in the following next step.
  • the 7alpha,12alpha-diol 56 (100 mg, 0.238 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with an excess of benzoyl chloride (0.20 mL, 1 .721 mmol, 7.2 Eq.) dissolved in a mixture of pyridine (0.3 mL) and dichloromethane (0.3 mL).
  • the reaction mixture was cooled in an ice-bath at 4 ⁇ C and stirred for 30 min after addition of 3 mL of ethyl acetate and 3 mL of a saturated aqueous solution of NaHC0 3 .
  • the 7alpha,12alpha-diol 56 (250 mg, 0.594 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with a limited amount of an extemporaneously prepared solution containing anhydrous THF (0.72 ml_), freshly distilled dihydropyrane (0.06 ml_ 0.658 mmol, 1 .1 Eq.) and p-toluenesulfonic acid (0.3 mg). The incomplete reaction was stopped by addition of an excess of a saturated NaHC0 3 solution.
  • the mixture of products containing the 12-mono-tetrahydropyranylether 58 was purified by TLC on fluorescent silica gel (petroleum ether/MTBE 1 :1 , x 4 developments) to give six different fractions controlled by analytical TLC in similar conditions : i) a less retained fraction (42 mg) at a much higher Rf corresponding probably to the bis-tetrahydropyranyl ether, ii) four major well-separated intermediate fractions of decreasing Rf values (A: 54 mg, B: 65 mg, C:29 mg and D:34 mg) and iii) a highly retained fraction (36 mg) corresponding to the unreacted diol 56.
  • the four intermediate fractions were employed without further purification in the next benzoylation step.
  • reaction was complete after 48 h for the two fractions C and D but was much slower for fractions A and B which were not totally benzoylated after 6 days at rt°. After this reaction time, the reaction mixture was cooled in an ice-bath at 4 ⁇ C and stirred for 30 min after addition of 1 .5 mL of ethyl acetate and 1 .5 mL of a saturated aqueous solution of NaHC0 3 .
  • the 7alpha,12alpha-diol 56 (343 mg, 0.82 mmol, 1 .0 Eq.) was stirred for 24 h at rt° with a limited amount of benzoyl chloride (0.121 mL, 1 .04 mmol, 1 .28 Eq.) dissolved in a mixture of pyridine (1 .3 mL) and dichloromethane (1 .3 mL).
  • the reaction mixture was cooled in an ice-bath at 4°C and stirred for 30 min after addition of 10 mL of ethyl acetate and 10 mL of a saturated aqueous solution of NaHC0 3 .
  • the crude product was purified by column chromatography on silica gel in similar conditions to give the pure mono-12alpha-benzoate 61 from the less retained fraction (228 mg) and the 7alpha,12alpha-dibenzoate by-product 57 from the more retained fraction (179 mg).
  • the 7alpha-hydroxy derivative 61 (100 mg, 0.19 mmol, 1 .0 Eq.) was stirred for 4 days at rt° in an extemporaneously prepared solution containing anhydrous THF (2 ml_), freshly distilled dihydropyrane (0.775 ml_) and p-toluenesulfonic acid (6 mg). The reaction was stopped by addition of an excess of a saturated NaHC0 3 solution.
  • Methyl 3alpha,7alpha,12alpha-trihydroxycholanate 55 (4.0 g, 9.5 mmol, 1 .0 Eq.) dissolved in dimethylformamide (40 ml_) was stirred for 2 h at rt° in the presence of 1 /-/-Imidazole (1 .35 g, 19.8 mmol, 2.1 Eq.) and a limited amount of tert- butyl-dimethylsilyl chloride (1 .71 g, 1 1 .3 mmol, 1 .2 Eq.).
  • reaction mixture was filtered on a column of Celite which was washed with an excess of toluene.
  • the combined filtrates were evaporated under reduced pressure.
  • the white extract was analyzed by TLC on fluorescent silica gel (dichloromethane/methanol 9:1 ), showing a major spot above the starting product.
  • This product was purified by column chromatography on silica gel in similar conditions to give the pure mono-3-ketone 69 (1 .15 g) as a white solid.
  • the 3-oxo-7alpha,12alpha-diol 69 (400 mg, 0.98 mmol, 1 .0 Eq.) was stirred for 24 h at rt° with a limited amount of benzoyl chloride (0.146 mL, 1 .25 mmol, 1 .28 Eq.) dissolved in a mixture of pyridine (1 .5 mL) and dichloromethane (1 .5 mL). The reaction mixture was cooled in an ice-bath at 4°C and stirred for 30 min after addition of 12 mL of ethyl acetate and 12 mL of a saturated aqueous solution of NaHC0 3 .
  • the crude product was purified by column chromatography on silica gel in similar conditions to give the pure mono-12alpha-benzoate 70 from the more eluted fraction (218 mg) and the 7alpha,12alpha-dibenzoate by-product 71 (vide infra) from the less eluted fraction (126 mg).
  • This dibenzoate 71 was obtained as a by-product of mono-benzoylation of 3- oxo-7alpha,12alpha-dihydroxy-24-methoxycholane (cf preceding step, above).
  • the 7alpha-hydroxy derivative 70 (120 mg, 0.23 mmol, 1 .0 Eq.) was stirred for 4 days at rt° in an extemporaneously prepared solution containing anhydrous THF (2.5 ml_), freshly distilled dihydropyrane (956 ⁇ _) and p-toluenesulfonic acid (8 mg). The reaction was stopped by addition of an excess of a saturated NaHC0 3 solution.
  • 17alpha-hydroxypregna-4-en-3,20-dione (“17alpha-hydroxyprogesterone”) (from Sigma)(320 mg, 0.968 mmol, 1 .0 Eq.) was stirred for 12 h under reflux with benzoyl chloride (0.640 mL, 5.513 mmol, 5.7 Eq.) dissolved in pyridine (8 mL) containing dimethylaminopyridine (177 mg, 1 .5 Eq.). The reaction mixture was cooled at 4°C and stirred for 30 min after addition of 5 mL of ethyl acetate and 5 mL of a saturated aqueous solution of NaHC0 3 .
  • Example 10 Preparation of 3 -(2-Hydroxy-4-azidobenzoyl)amidopropyl- oxypregn-5-en-20-one (77) and 3 -(2-Nitro-5-azidobenzoyl)amidopropyloxy- pregn-5-en-20-one (78)
  • Example 1 1 .1 . Preparation of 7oc-(2-Hydroxy-4-azidobenzoyl)amidopropyloxy (5oc)pregnane-3,20-dione (79) and 7a-(2-Nitro-5-azidobenzoyl)amidopropyloxy(5oc) pregnane-3,20-dione (80)
  • Example 1 1 .2. Preparation of 7p-Tetrahydropyranyloxy(5oc)pregnane-3,20- dione (isomer S) (81 ), 7p-Tetrahydropyranyloxy(5oc)pregnane-3,20-dione (isomer R) (82), 7oc-Tetrahydropyranyloxy(5oc)pregnane-3,20-dione (isomer S) (83) and 7a- Tetrahydropyranyloxy(5a)pregnane-3,20-dione (isomer R) (84)
  • Example 1 1 .4. Preparation of 7 -Tetrahydropyranyloxy-3-ethylenedioxy (5oc)pregnan-20-one (isomer S) (88) and 7 -Tetrahydropyranyloxy-3-ethylenedioxy (5oc)pregnan-20-one (isomer R) (89)
  • Compound (90) is prepared by benzoylation of 7oc-hydroxy(5P)pregnane-3,20- dione obtained in several steps from a 20-mono-dioxolanated 4,6-dien-3-one precursor by selective 6oc,7oc-epoxidation with m-chloroperbenzoic acid, catalytic hydrogenation and ketal hydrolysis (Lai et al., Steroids 1983, 42, 707-71 1).
  • Compound (91 ) is prepared by acylation of 7alpha-amino-3,20- bisethylenedioxypregn-5-ene obtained via reduction of the oxime derivative from a
  • Example 14 Preparation of 7oc-(2'-Hydroxy)ethylpregn-4-ene-3,20-dione (92) and 7a-(2'-Tetrahydropyranyloxy)ethylpregn-4-ene-3,20-dione (unseparated R/S isomers) (93)
  • These compounds are prepared by tetrahydropyranylation of a 7alpha- hydroxyethyl group obtained by LiAIH 4 reduction of a 7alpha-methylene carboxylic methyl ester side-chain synthesized in several steps, according to a reported procedure using malonic alkylation of a 7-bromopregn-5-ene-3,20-bis-ethyleneketal precursor, followed by decarboxylation, esterification and hydrolysis of the 3,20- bisdioxolane protecting group (Duval et al., J. Steroid Biochem. 1985, 22, 67-78).
  • Example 15.1 Preparation of 1 1 oc-(2-Hydroxy-4-azidobenzoyl)amidopropyl- oxypregn-4-ene-3,20-dione (94) and 1 1 oc-(2-Nitro-5-azidobenzoyl)amidopropyloxy- pregn-4-ene-3,20-dione (95)
  • This compound is prepared by tetrahydropyranylation (and TLC separation of R/S isomers) of 1 1 alpha-(2'-hydroxy)ethyloxypregn-4-ene-3,20-dione obtained in several steps from from 1 1 alpha-hydroxypregn-5-ene-3,20-bis-ethyleneketal as described above for compound 85.
  • Example 16 Preparation of 17oc-Tetrahydropyranyloxy(5P)pregnan-3,20- dione (less retained isomer)(100) and 17oc-Tetrahydropyranyloxy(5P)pregnan- 3,20-dione (more retained isomer)(101 )
  • Example 17 Preparation of 21-Tetrahydropyranyloxypregn-4-ene-3,20- dione (unseparated mixture of R/S isomers (102) and (103))
  • Example 18.1 Preparation of 7oc-Tetrahydropyranyloxy-3p-benzoyloxy(5oc) pregnan-20-one (unseparated mixture of R/S isomers)(104), 7oc-Tetrahydropyranyl- oxy-3p-benzoyloxy(5oc)pregnan-20-one (isomer S)(105) and 7oc-Tetrahydropyranyl- oxy-3p-benzoyloxy(5oc)pregnan-20-one (isomer R)(106)
  • Compound (37) is prepared (cf above) as a precursor for the synthesis of active compounds (39), (40) and (41 ).
  • Compound (53) is obtained as a less active 17-OTHP (S) isomer of the active compound (51 ) (cf above).
  • Example 21 Preparation of 7oc/p-Tetrahydropyranyloxypregn-5-ene-3p,20oc/p- di-i-butyldimethylsilyl ether (three separated isomers) (1 14), (1 15) and (1 16).
  • These compounds are prepared by benzoylation of a mixture of isomeric trihydroxy derivatives resulting from reduction of both 3- and 20-keto groups of a fully 3,20-deprotected by-product obtained as a by-product in the selective 3-ketal hydrolysis of the 1 1 oc-hydroxy(5P)pregnane-3,20-bisethyleneketal precursor employed in the synthesis of the active compound 3 ⁇ / ⁇ -1 1 oc-dibenzoyloxy (5 )pregnan-20-one (20) (cf above).
  • This compound is prepared by esterification of chenodeoxycholic acid (purchased from Aldrich) to methyl chenodeoxycholanate, followed by bis- tetrahydropyranylation.
  • This compound is prepared by selective oxidation of the 3alpha-hydroxy group of methyl chenodeoxycholanate (cf above ⁇ 23.1 ) to a 3-ketone with silver carbonate reagent (cf above example 8, compound 56) and 7-benzoylation.
  • This compound is prepared by reduction of methyl 3,7-bis-tetrahydropyranyl- oxychenodeoxydeoxycholanate (cf above ⁇ 23.1 ) with LiAIH 4 to a 24-cholanol then converted to a 24-benzylether.
  • This compound is prepared by tetrahydropyranylation of the 3-monobenzoate- 7-hydroxy precursor obtained by hydrolysis of 3,7-bis-tetrahydropyranyloxy- chenodeoxycholane-24-benzylether (129) to a 3,7-diol followed by selective 3- monobenzoylation.
  • This compound is prepared by esterification of chenodeoxycholic acid (from Aldrich) with benzyl chloride and bis-tetrahydropyranylation.
  • This compound is prepared by 3-monobenzoylation of the benzyl chenodeoxycholanate (cf above ⁇ 23.6) followed by 7-tetrahydropyranylation.
  • This compound is prepared by 3-monobenzoylation of methyl deoxycholanate and 12-tetrahydropyranylation followed by TLC separation of R/S isomers.
  • This compound is prepared by reduction of methyl 3,12-bis- tetrahydropyranyloxy-deoxycholanate (cf above ⁇ 24.1 ) with LiAIH 4 to the 24- cholanol then converted to a 24-benzylether.
  • This compound is prepared by tetrahydropyranylation (and TLC separation of R/S isomers) of a 3-monobenzoate-12-hydroxy precursor obtained by hydrolysis of 3,12-bis- tetrahydropyranyloxydeoxycholane 24-benzylether (129) to a 3,12-diol and selective 3-monobenzoylation.
  • Example 26 Preparation of 3- or 7-mono-substituted (5oc-H)androstane derivatives: 3p-Benzoylamido(5oc)androstane [40212-36-0] (138), 3oc-Benzoylamido (5oc)androstane [40212-36-0] (139), 3p-(/V-Methyl)-benzoylamido(5oc) androstane (140) and 7p-Benzoyl-amido(5oc)androstane (142)
  • These compounds are prepared from 3- or 7-oxo(5oc)androstane precursors via oximation, reduction of oxime to amine, acylation to benzamide and N- methylation.
  • Example 27.1 Preparation of 7oc-Benzoyloxy-17p-tetrahydropyranyloxy(5P) androstan-3-one (less retained isomer) (143) and 7oc-Benzoyloxy-17p-tetrahydro- pyranyloxy(5 )androstan-3-one (more retained isomer) (144)
  • Example 27.2 Preparation of 7oc,17p-Dibenzoyloxy(5P)androstan-3-one (145) This compound is prepared as described above for 7oc-benzoyloxy-17p- tetrahydropyranyloxy(5 )androstan-3-one isomers (143) and (144) but without prior tetrahydropyranylation.
  • Example 28 Preparation of 7,11-disubstituted (5 )pregnane derivatives (205) and (206)
  • the reaction mixture was extracted by pouring it in 800 ml_ of water.
  • the solid precipitate of steroid derivative was collected by filtration and washed with water.
  • the solid residue was extracted with ethyl acetate.
  • the organic layer was washed with water, filtered on a phase-separating paper (Whatman), evaporated to dryness under reduced pressure and dried by azeotropic distillation with toluene under reduced pressure.
  • the dry product (8.55 g) was analyzed by TLC on fluorescent silica gel (petroleum ether/ethyl acetate 5:1 ).
  • the enone derivative 199 (3.0 g, 6.746 mmol, 1 .0 Eq.) was dissolved in hot t- butanol (150 ml_) and stirred under reflux for 3.5 h in the presence of tetrachlorobenzoquinone (4.0 g, 16.27 mmol, 2.4 Eq.) until UVmax absorbance of extracted aliquots shifted from 240 to 285 nm.
  • the reaction mixture was filtered on a slightly heated basic alumina column and evaporated.
  • the dry product (2.8 g) was analyzed by TLC on fluorescent silica gel (petroleum ether/ethyl acetate 3:1 ) revealing the presence of a slightly more polar minor contaminant.
  • the colored crude residue was purified by flash-chromatography on silica gel (230-400 mesh) using petroleum ether/ethyl acetate 3:1 as eluent to give a sample (1 .16 g) of pure dienone 200 whereas the other fractions were further purified by preparative TLC on fluorescent silica gel (petroleum ether/ethyl acetate 3:1 ) to give an additional sample (0.68 g) of dienone.
  • the dienone derivative 200 (682 mg, 1 .541 mmol, 1 .0 Eq.) was dissolved in dichloromethane (90 mL) and stirred under argon atmosphere for 3 days at rt° in the presence of m-chloroperbenzoic acid (430 mg, 2.492 mmol, 1 .62 Eq.). The reaction being still incomplete, an additionnal amount of m-chloroperbenzoic acid (215 mg, 1 .246 mmol, 0.81 Eq) was added and stirring was prolunged for 4 days until starting product was totally transformed.
  • reaction mixture cooled in an ice-bath, was inactivated by addition of an excess of an aqueous 10% sodium sulfite solution (100 mL).
  • aqueous 10% sodium sulfite solution 100 mL
  • the dichloromethane organic layer was decanted, washed with a saturated aqueous solution of sodium bicarbonate and evaporated.
  • the mono-epoxide 201 (447 mg, 0.974 mmol, 1 .0 Eq.) dissolved in a dioxane- 95% ethanol 1 :1 v/v mixture containing 0.8% pyridine (45 mL) was introduced in a glass hydrogenation apparatus and magnetically stirred under hydrogen at atmospheric pressure, for 12 h at 30 ⁇ , in the presence of 10% Pd-C catalyst (391 mg). The progression of the reaction was monitored by TLC (vide infra) on extracted aliquots.
  • the crude product was purified by flash-chromatography on silica gel (230- 400 mesh) using petroleum ether/ethyl acetate 2:1 as eluent to give a pure sample (125 mg) of (5beta-H)-7alpha-hydroxy compound 202 and slightly impure fractions (287 mg) which were repurified.
  • the 7a-hydroxy derivative 202 (216 mg, 0.467 mmol, 1 .0 Eq.) was stirred for 1 h at rt° then for 12h at 4° C in an extemporaneously prepared solution containing anhydrous THF (4.5 mL), freshly distilled dihydropyrane (0.9 mL) and p- toluenesulfonic acid (4.5 mg). The reaction was stopped by addition of an excess of a saturated NaHC0 3 solution.
  • the crude product was purified by flash-chromatography on silica gel (230- 400 mesh) using petroleum ether/ethyl acetate 4:1 as eluent to give a pure sample (219 mg) of the unseparated tetrahydropyranyl ether R/S mixture 203.
  • the 1 1 a-ieri-butyldimethylsilyl derivative 203 (175 mg, 0.320 mmol, 1 .0 Eq.) dissolved in THF (2.4 mL) was stirred for 2 h at 4°C then for 48 h at rt° after addition of a commercial 1 M solution of tetra-butylammonium fluoride (1 .147 mL, 1 .147 mmol, 0.300 g, 3.59 Eq.) in THF.
  • the crude 1 l alpha-hydroxy product 204 was employed in the next step without further purification.
  • the 1 1 oc-hydroxy derivative 204 (135 mg, 0.312 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with benzoyl chloride (0.20 ml_, 1 .723 mmol, 5.52 Eq.) dissolved in pyridine (5.5 ml_).
  • reaction mixture was cooled at 4°C, stirred for 30 min after addition of 25 ml_ of ethyl acetate and 25 ml_ of a saturated aqueous NaHC0 3 solution.
  • the crude product was purified by preparative TLC on fluorescent silica gel (petroleum ether/ethyl acetate 4:1 , x 9 developments) which gave a less polar fraction (45 mg), a more polar fraction (17 mg) and an intermediate fraction containing a mixture of these two fractions (49 mg) which was further purified by a similar preparative TLC (petroleum ether/ethyl MTBE 2:1 , x 7 developments) leading to two similarly enriched less- and more polar fractions (13 mg and 27 mg).
  • Methyl 3a,6a-dihydroxycholanate (“methyl hyodeoxycholate”) (200 mg, 0.492 mmol, 1 .0 Eq.) dissolved in toluene (40 mL) was magnetically stirred for 12 h under reflux in a Dean-Stark water trap in the presence of 4.0 g of Ag 2 C0 3 /Celite reagent
  • reaction mixture was filtered on a column of Celite which was washed with an excess of toluene.
  • the combined filtrates were evaporated under reduced pressure.
  • the white extract was analyzed by TLC on fluorescent silica gel (petroleum ether/ethyl acetate 1 :1 ), showing a major spot above the starting product.
  • This mono-3-oxo product 207 was employed without further purification in the following next step.
  • the 6a-hydroxy derivative 207 (80 mg, 0.198 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with an excess of benzoyl chloride (0.14 mL, 1 .206 mmol, 6.1 Eq.) dissolved in a mixture of pyridine (2.2 mL). The reaction mixture was cooled in an ice-bath at 4 ⁇ C and stirred for 30 min after addition of 9 mL of ethyl acetate and 9 mL of a saturated aqueous NaHC0 3 solution.
  • the 6a-hydroxy derivative 207 (150 mg, 0.371 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with a limited amount of an extemporaneously prepared solution containing anhydrous THF (4 mL), freshly distilled dihydropyrane (0.80 mL 8.768 mmol, 23.6 Eq.) and p-toluenesulfonic acid (0.4 mg). The reaction was stopped by addition of an excess of a saturated aqueous NaHC0 3 solution.
  • the 6-hydroxy derivative 212 (397 mg, 0.721 mmol, 1 .0 Eq.) was stirred for 12 h at rt° with benzoyl chloride (1 mL, 1 .723 mmol, 1 1 .9 Eq.) dissolved in pyridine (15 mL).
  • reaction mixture was cooled at 4 ⁇ ⁇ , stirred for 1 h after addition of 60 mL of ethyl acetate and 65 mL of a saturated aqueous NaHC0 3 solution.
  • the crude 1 l alpha-hydroxy product 214 was employed in the next step without purification.
  • reaction mixture was cooled at 4 ⁇ C, stirred for 1 h after addition of 10 mL of ethyl acetate and 10 mL of a saturated aqueous NaHC0 3 solution.
  • NCI H295R cells were grown in 75-cm 2 culture flasks at 37 °C in a 5% C0 2 atmosphere .
  • the culture medium consisted of a 1 :1 mixture of DMEM and Ham's F- 12 medium, supplemented with L-glutamine (2 mM), antibiotics (50 ⁇ g mL streptomycin, 50 U/mL penicillin) and 2% Ultroser G, Ultroser SF (Biorad) and a commercial mixture of insulin, transferin and sodium selenite (ITS + 1 , Sigma).
  • Cells were harvested with trypsin (0.05%)-EDTA (0.02%) and resuspended in culture medium. Cell viability always exceeded 95%.
  • Quantitative PCR was performed in a final volume of 20 ⁇ containing 5 ⁇ of a 60-fold dilution of the RT reaction medium, 15 ⁇ of reaction buffer from the FastStart DNA Master Plus SYBER Green Kit (Roche Diagnostics, Basel, Switzerland), and 10 pmol of the specific forward and reverse primers (Operon Biotechnologies, Cologne, Germany) (Table 1 ).
  • Standard curves were prepared for each target and reference gene. Each assay was performed in duplicate, and validation of the real-time PCR runs was assessed by evaluation of the melting temperature of the products and by the slope and error obtained with the standard curve. The analyses were performed using Light-Cycler software (Roche Diagnostics). Results are expressed as relative levels after normalization by G3PDH mRNA.
  • Table 1 Specific oligonucleotide PCR primers employed for the quantification of mRNA of ABC transporters
  • MRP1/ABCC1 MRP2/ABCC2
  • BCRP/ABCG2 BCRP/ABCG2
  • Low amounts of MRP1 mRNA were found in both R7 and H295R cells whereas a low level of BCRP was present in R7 cells only. No MRP2 could be detected in both cells lines.
  • H295R cell line cells were seeded into 24-well plates and incubated at 37° C in a 5% CQ 2 atmosphere.
  • H295R cell line cells were seeded into 24-well plates and, after cell attachment (24 h), culture medium in each well was replaced by medium containing three concentrations (10 ⁇ 5 M, 10 ⁇ 6 M, 10 ⁇ 7 M) of steroid derivatives according to the invention prepared from an initial solution at 10 ⁇ 2 M in DMSO or the same three concentrations of cyclosporine A prepared from an initial solution at 10 ⁇ 2 M in water as control.
  • Doxorubicine (DOXO) at 10 ⁇ 6 M was added shortly thereafter to each well.
  • K562/R7 cell lines For K562/R7 cell lines, cells were distributed into 24-well plates and incubated with 600 ⁇ _ of medium containing the compounds of the invention or cyclosporine A and doxorubicin at the same concentrations as for H295R cells. After 24 h incubation, 500 ⁇ of the culture medium were removed and replaced by 500 ⁇ of fresh medium containing 1 ⁇ of [ 3 H]thymidine. Cells were incubated for another 24 hours and pelleted by centrifugation (1000 rpm, 5 min), the medium was aspirated off, cells were washed twice with phosphate-buffered saline (PBS) and radioactivity was measured after TCA precipitation as above.
  • PBS phosphate-buffered saline
  • each concentration of steroid or cyclosporine A was tested in triplicate and controls, using support medium only, were performed. At least three different experiments were performed for each cell type.
  • Results were expressed as the percentage of [ 3 H]thymidine incorporation in surviving cells in each well compared to untreated cells (Table 2).
  • Table 2 [ 3 H]thymidine incorporation in surviving cells after treatment with doxorubicin (10 "6 M) in the presence of steroid modulators (10 ⁇ 5 M)
  • K562/R7 cells (10 000/well) were seeded into 96-well plates and incubated with 200 ⁇ _ of medium containing the compounds of the invention or cyclosporine A at three concentrations (10 ⁇ 5 M, 10 ⁇ 6 M 10 ⁇ 7 M). Doxorubicin at 10 ⁇ 6 M was then added to each well. After incubation for 72 h, 20 ⁇ _ of MTT reagent (5 mg/mL in PBS buffer) were added to each well and the plate was further incubated for 4 h at 37°C, allowing viable cells to change the yellow MTT into dark-blue formazan crystals.
  • Table 2 bis Surviving cells measured with MTT after treatment with doxorubicin (10 ⁇ 6 M) in the presence of steroid modulators (10 ⁇ 5 M)
  • IC 50 values defined as the concentration of cytotoxic drugs inhibiting cell growth by 50% were determined by treatment of resistant K562/R7 and H295R cells (150 000 cells/well) for 24 h with increasing concentrations of several cytotoxic drugs (from 10 ⁇ 8 to 10 ⁇ 4 M)( Figures 1 and 2). After treatment, the number of surviving cells was evaluated by the incorporation of [ 3 H]thymidine as described above.
  • IC50 for doxorubicin (DOXO) by the steroid modulators was measured by treatment of resistant R7 and H295R cells (150 000 cells/well) for 24 h with increasing concentrations of DOXO (from 10 ⁇ 8 to 10 ⁇ 4 M) in the presence or absence of appropriate concentrations of steroids or of cyclosporine A . ( Figures 3 and 4). Sensitive parental K562 cells were also treated with the same increasing concentrations of DOXO (from 10 ⁇ 8 to 10 ⁇ 4 M) in the absence of steroids, as a control.
  • daunorubicin in the presence of steroid modulators according to the invention i.e. compounds having formula (I) was measured by flow cytometry using a reported procedure (G. Comte et at, J. Med. Chem., 44: 763-768, 2001 ).
  • K562 or R7 cells (1 .10 6 cells) were incubated for 1 h at 37° C with 1 ml_ RPMI 1640 medium containing daunorubicin at 10 ⁇ , in the presence or absence of compounds of the inention (10 ⁇ ).
  • hPXR human pregnane X receptor
  • mice of group 4 showed a delay in the development of tumour by comparison with mice of groups 1 , 2 and 3. Moreover, in mice of group 4, the tumour volume remains low and stable after 40 days of treatment allowing a longer survival time for these mice ( Figures 7 and 8). These results suggested an in vivo efficiency of (33) derivative as adjuvant to chemotherapy treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne un composé de formule (I) pour son emploi dans l'inversion ou l'inhibition de la résistance pléiotrope.
PCT/EP2010/070141 2009-12-18 2010-12-17 Nouveaux inhibiteurs stéroïdiens de pgp pour emploi dans l'inhibition de la résistance pléiotrope WO2011073419A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10788352A EP2512485A1 (fr) 2009-12-18 2010-12-17 Nouveaux inhibiteurs stéroïdiens de pgp pour emploi dans l'inhibition de la résistance pléiotrope
JP2012543802A JP2013514338A (ja) 2009-12-18 2010-12-17 多剤耐性を抑制するための使用のためのｐｇｐの新規ステロイド阻害剤
US13/516,860 US20120309728A1 (en) 2009-12-18 2010-12-17 New steroid inhibitors of pgp for use for inhibiting multidrug resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306282 2009-12-18
EP09306282.6 2009-12-18

Publications (1)

Publication Number Publication Date
WO2011073419A1 true WO2011073419A1 (fr) 2011-06-23

Family

ID=42035906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/070141 WO2011073419A1 (fr) 2009-12-18 2010-12-17 Nouveaux inhibiteurs stéroïdiens de pgp pour emploi dans l'inhibition de la résistance pléiotrope

Country Status (4)

Country Link
US (1) US20120309728A1 (fr)
EP (1) EP2512485A1 (fr)
JP (1) JP2013514338A (fr)
WO (1) WO2011073419A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102964417A (zh) * 2012-11-30 2013-03-13 华中药业股份有限公司 17-羟基四氢吡喃醚甾族化合物的合成方法
CN103314004A (zh) * 2011-12-02 2013-09-18 台州市海盛化工有限公司 5,7-孕甾二烯-3,20-二酮-二乙二缩酮新的制备方法
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
CN109912676A (zh) * 2019-03-07 2019-06-21 华东师范大学 一种3β-熊去氧胆酸的制备方法
CN116063371A (zh) * 2023-03-15 2023-05-05 苏州当量生物医药有限公司 3-[3-(胆酰胺丙基)二甲氨基]丙磺酸内盐的合成方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120277201A1 (en) * 2011-04-28 2012-11-01 Marchewitz Eric D Use of hydroxyprogesterone derivatives for enhancing health and physical performance
CN104327147B (zh) * 2014-06-04 2016-11-23 正源堂（天津滨海新区）生物科技有限公司 一种麦角甾醇类化合物及其制备方法与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914420A (en) * 1972-12-19 1975-10-21 Roussel Uclaf Novel antiandrogenic compounds
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5641767A (en) * 1994-09-14 1997-06-24 Hoechst Aktiengesellschaft Modified bile acids process for their preparation and their use
WO1997027211A1 (fr) * 1996-01-23 1997-07-31 Satish Batra Nouveaux carbamates de steroides en tant qu'agents de potentialisation
WO2002087552A2 (fr) * 2001-05-01 2002-11-07 Mcgill University Neuroprotection mediee par androgene et ses utilisations
WO2006007910A1 (fr) * 2004-07-20 2006-01-26 Santhera Pharmaceuticals (Schweiz) Ag Utilisation de steroides non-glucocorticoides pour le traitement d'une dystrophie musculaire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914420A (en) * 1972-12-19 1975-10-21 Roussel Uclaf Novel antiandrogenic compounds
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5641767A (en) * 1994-09-14 1997-06-24 Hoechst Aktiengesellschaft Modified bile acids process for their preparation and their use
WO1997027211A1 (fr) * 1996-01-23 1997-07-31 Satish Batra Nouveaux carbamates de steroides en tant qu'agents de potentialisation
WO2002087552A2 (fr) * 2001-05-01 2002-11-07 Mcgill University Neuroprotection mediee par androgene et ses utilisations
WO2006007910A1 (fr) * 2004-07-20 2006-01-26 Santhera Pharmaceuticals (Schweiz) Ag Utilisation de steroides non-glucocorticoides pour le traitement d'une dystrophie musculaire

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
A.F. GAZDAR ET AL., CANCER RESEARCH, vol. 50, 1990, pages 5488 - 5496
AMANN A; OURISSON G; LUU B, SYNTHESIS, 1987, pages 1002 - 4
B. ISENBERG ET AL., EUR. J. BIOCHEM, vol. 268, 2001, pages 2629 - 2634
BERGE ET AL., J. PHARM. SD, vol. 66, 1977, pages 1
C.B. LOZZIO; B.B. LOZZIO, BLOOD, vol. 45, 1975, pages 331 - 334
C.Y., CUILLERON, THESE DE DOCTORAT D'ETAT, 1971
CHIA-PING HUANG YANG ET AL: "Progesterone Interacts with P-Glycoprotein in Multidrug-resistant Cells and in the Endometrium of Gravid Uterus", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 264, no. 2, 15 January 1989 (1989-01-15), pages 782 - 788, XP002082470, ISSN: 0021-9258 *
D.J. GRUOL ET AL., CANCER RES, vol. 54, 1994, pages 3088 - 3091
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HEGNER, P. ET AL: "Constituents of the adrenal cortex and related substances. LXI. 11-Ketoprogesterone", XP002636038, retrieved from STN Database accession no. 1944:10161 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HOSODA, HIROSHI ET AL: "Chemical conversion of corticosteroids to 3.alpha.,5.alpha.-tetrahydro derivatives. Synthesis of allotetrahydro-11-deoxycortisol glucuronides", XP002636040, retrieved from STN Database accession no. 1986:443183 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KIRK, DAVID N. ET AL: "D-Homosteroids. V. Mechanism of D-homoannulation of 17.alpha.-hydroxypregnan-20-ones with boron trifluoride", XP002636039, retrieved from STN Database accession no. 1975:564421 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LARDON, A. ET AL: "Bile acids and related compounds. XVIII. Simplified preparation of 11-cholenic methyl esters by thermal cleavage of 12-benzoxy derivatives", XP002636037, retrieved from STN Database accession no. 1943:37491 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2007, CAI C ET AL: "Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.", XP002636042, Database accession no. NLM17003774 *
DUVAL ET AL., J. STEROID BIOCHEM., vol. 22, 1985, pages 67 - 78
E. TEODORI ET AL., CURRENT DRUG TARGETS, vol. 7, 2006, pages 896 - 909
E. TEODORI ET AL., II FARMACO, vol. 57, 2002, pages 385 - 415
E.P. BRUGGEMANN ET AL., J BIOL CHEM, vol. 264, 1989, pages 15483 - 15488
F. DESCOTES ET AL., BREAST CANCER RES. TREAT., vol. 49, 1998, pages 135 - 143
F.J. PEREZ-VICTORIA ET AL., CELL MOL LIFE SCI, vol. 60, 2003, pages 526 - 535
F6TIZON M.; BALOGH V.; GOLFIER M., J. ORG. CHEM., vol. 36, 1971, pages 1339 - 41
FETIZON M.; BALOGH V.; GOLFIER M., J. ORG. CHEM., vol. 36, 1971, pages 1339 - 41
FIESER L., REAGENTS FOR ORGANIC SYNTHESIS, vol. 2, pages 363
G. COMTE ET AL., J. MED. CHEM., vol. 44, 2001, pages 763 - 768
G. LEMAIRE ET AL., TOXICOL. SCI., vol. 91, 2006, pages 501 - 509
GRUOL DONALD J ET AL: "Evidence for the locations of distinct steroid and Vinca alkaloid interaction domains within the murine mdr1b P-glycoprotein.", MOLECULAR PHARMACOLOGY, vol. 62, no. 5, November 2002 (2002-11-01), pages 1238 - 1248, XP002636035, ISSN: 0026-895X *
HEGNER, P. ET AL: "Constituents of the adrenal cortex and related substances. LXI. 11-Ketoprogesterone", HELVETICA CHIMICA ACTA , 26, 721-9 CODEN: HCACAV; ISSN: 0018-019X, 1943 *
HOSODA, HIROSHI ET AL: "Chemical conversion of corticosteroids to 3.alpha.,5.alpha.-tetrahydro derivatives. Synthesis of allotetrahydro-11-deoxycortisol glucuronides", CHEMICAL & PHARMACEUTICAL BULLETIN , 33(10), 4281-7 CODEN: CPBTAL; ISSN: 0009-2363, 1985 *
I. RAAD ET AL., BIOORG. MED. CHEM., vol. 14, 2006, pages 6979 - 6987
J. ROBERT, EXPERT OPIN INVESTIG DRUGS, vol. 7, 1998, pages 929 - 939
J. ROBERT; C. JARRY: "Multidrug resistance reversal agents", J MED CHEM, vol. 46, 2003, pages 4805 - 4817
K.M. BARNES ET AL., BIOCHEMISTRY, vol. 35, 1996, pages 4820 - 4827
KATOH MIKI ET AL: "Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 12, no. 4, February 2001 (2001-02-01), pages 505 - 513, XP002578233, ISSN: 0928-0987 *
KIRK, DAVID N. ET AL: "D-Homosteroids. V. Mechanism of D-homoannulation of 17.alpha.-hydroxypregnan-20-ones with boron trifluoride", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999) , (15), 1450-5 CODEN: JCPRB4; ISSN: 0300-922X, 1975 *
L.M. GREENBERGER, J BIOL CHEM, vol. 268, 1993, pages 11417 - 11425
LAI ET AL., STEROIDS, vol. 42, 1983, pages 707 - 711
LARDON, A. ET AL: "Bile acids and related compounds. XVIII. Simplified preparation of 11-cholenic methyl esters by thermal cleavage of 12-benzoxy derivatives", HELVETICA CHIMICA ACTA , 25, 1444-52 CODEN: HCACAV; ISSN: 0018-019X, 1942 *
LEONESSA ET AL., J. MED. CHEM, vol. 45, 2002, pages 390 - 398
LI Y ET AL: "Comparison of steroid substrates and inhibitors of P-glycoprotein by 3D-QSAR analysis", JOURNAL OF MOLECULAR STRUCTURE, ELSEVIER, AMSTERDAM, NL, vol. 733, no. 1-3, 3 January 2005 (2005-01-03), pages 111 - 118, XP004633870, ISSN: 0022-2860 *
M. PEER ET AL., MINI REV IN MED CHEM, vol. 5, 2005, pages 165 - 172
M.M. GOTTESMAN ET AL., NAT REV CANCER, vol. 21, 2002, pages 48 - 58
MAPPUS E.; CUILLERON C.Y., J. CHEM. RES., 1979, pages 42 - 3
MAPPUS E.; CUILLERON C.Y., J. CHEM. RES., vol. 1979, no. S, pages 42 - 3
MAPPUS E.; CUILLERON C.Y., STEROIDS, vol. 33, 1979, pages 693 - 718
MAPPUS ET AL., STEROIDS, vol. 38, 1981, pages 607 - 632
O. JOLY-PHARABOZ ET AL., J STEROID BIOCHEM. MOL. BIOL., vol. 73, 2000, pages 237 - 249
POMMERENKE E W ET AL: "Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells", CANCER LETTERS, NEW YORK, NY, US LNKD- DOI:10.1016/0304-3835(90)90060-B, vol. 55, no. 1, 19 November 1990 (1990-11-19), pages 17 - 23, XP023163247, ISSN: 0304-3835, [retrieved on 19901119] *
PROSTATE CANCER AND PROSTATIC DISEASES 2007 LNKD- PUBMED:17003774, vol. 10, no. 1, 2007, pages 39 - 45, ISSN: 1365-7852 *
ROY; RAY, STEROIDS, vol. 60, 1995, pages 530 - 533
S.G. ALLER ET AL., SCIENCE, vol. 323, 2009, pages 1718 - 1722
T.W. LOO ET AL., BIOCHEMISTRY, vol. 43, 2004, pages 12081 - 12089
T.W. LOO; D.M. CLARKE, J BIOL CHEM, vol. 276, 2001, pages 36877 - 36880
VO QUANG D ET AL: "Identification of P-glycoprotein mutations causing a loss of steroid recognition and transport", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 29, 16 July 1999 (1999-07-16), pages 20318 - 20327, XP002636036, ISSN: 0021-9258 *
YANG C-P H ET AL: "DIFFERENTIAL TRANSPORT PROPERTIES OF TWO MDR GENE PRODUCTS ARE DISTINGUISHED BY PROGESTERONE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 265, no. 18, 25 June 1990 (1990-06-25), pages 10282 - 10288, XP008121451, ISSN: 0021-9258 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103314004A (zh) * 2011-12-02 2013-09-18 台州市海盛化工有限公司 5,7-孕甾二烯-3,20-二酮-二乙二缩酮新的制备方法
CN103314004B (zh) * 2011-12-02 2015-07-08 台州市海盛制药有限公司 5,7-孕甾二烯-3,20-二酮-二乙二缩酮新的制备方法
CN102964417A (zh) * 2012-11-30 2013-03-13 华中药业股份有限公司 17-羟基四氢吡喃醚甾族化合物的合成方法
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
US10869875B2 (en) 2015-10-26 2020-12-22 MAX BioPharma, Inc. Oxysterols and Hedgehog signaling
CN109912676A (zh) * 2019-03-07 2019-06-21 华东师范大学 一种3β-熊去氧胆酸的制备方法
CN109912676B (zh) * 2019-03-07 2021-08-27 上海科骊科生物技术有限公司 一种3β-熊去氧胆酸的制备方法
CN116063371A (zh) * 2023-03-15 2023-05-05 苏州当量生物医药有限公司 3-[3-(胆酰胺丙基)二甲氨基]丙磺酸内盐的合成方法

Also Published As

Publication number Publication date
US20120309728A1 (en) 2012-12-06
JP2013514338A (ja) 2013-04-25
EP2512485A1 (fr) 2012-10-24

Similar Documents

Publication Publication Date Title
WO2011073419A1 (fr) Nouveaux inhibiteurs stéroïdiens de pgp pour emploi dans l'inhibition de la résistance pléiotrope
US8829213B2 (en) Liver X receptor agonists
JP3292928B2 (ja) 新規なプレグナ−１，４−ジエン−３，２０−ジオン−１６，１７−アセタール−２１−エステル、その製法および抗炎症用医薬組成物
EP1853619B1 (fr) 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene pour la mise en oeuvre dans le traitement d'une maladie de la prostate
JP7021080B2 (ja) ファルネソイドｘ受容体調節剤
JP3333210B2 (ja) 新規プレドニソロン誘導体および該化合物を含有する薬剤
US5962443A (en) 19-nur-pregnane steroids as neurochemical initiators of change in human hypothalamic function
EP2298316A1 (fr) Procedes de traitement therapeutique
BG107289A (bg) 3 - азот - 6,7 - дикислородни стероиди и тяхното използване
TW201006474A (en) Natural products including an anti-flammatory pharmacore and methods of use
US20070032464A1 (en) Methods of treating cancers
SK79693A3 (en) Novel steroids
JP2000501732A (ja) 抗炎症薬として有用な新規ステロイドナイトライト／ナイトレートエステル誘導体
JP2010522732A (ja) 鉱質コルチコイド受容体アンタゴニスト
JP2010522233A (ja) 抗炎症剤及び抗癌剤であるグルココルチコイドの脂肪酸エステル
JP2000501733A (ja) 抗炎症薬として有用な新規ステロイドナイトライトエステル誘導体
EP0675897B1 (fr) Nouveaux steroides
SK282061B6 (sk) Makrolidy, spôsob ich prípravy a farmaceutický prostriedok
FI86190C (fi) Analogifoerfarande foer framstaellning av en terapeutiskt verksam androstan-17 -karboxylsyraester.
JPH08510988A (ja) 改良された抗アンドロゲン
NZ256796A (en) Estrene steroid-containing medicament for nasal administration
JPS6355488B2 (fr)
JP2566574B2 (ja) 抗癌および抗肥満剤として有用なステロイド
JP5826750B2 (ja) 炎症性疾患および自己免疫疾患へのステロイド化合物の使用
PL112152B1 (en) Process for preparing novel derivatives of 9-chloroprednisolone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788352

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012543802

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010788352

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13516860

Country of ref document: US